Autopsy report · NCT04728646

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

“Due to difficulty enrolling subjects whom had not meet the inclusion criteria”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Massachusetts Eye and Ear Infirmary

Sponsor type

University, hospital or other

Conditions

Graft Vs Host Disease

Interventions

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use; Regular dissolvable intracanalicular plug

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Sirolimus for the Treatment of Hyperinsulinism
  “Due to strict inclusion and exclusion criteria no subjects were enrolled” (85% match in meaning)
• The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
  “Difficulty enrolling eligible subjects” (82% match in meaning)
• Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace
  “Inability to enroll subjects” (80% match in meaning)
• Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
  “Failure to enroll a suitable number of qualified subjects.” (79% match in meaning)
• The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
  “Inability to recruit eligible subjects” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.